Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-13
2005-09-13
Woitach, Joseph (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C424S233100
Reexamination Certificate
active
06943153
ABSTRACT:
Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
REFERENCES:
patent: 5641749 (1997-06-01), Yan et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5814618 (1998-09-01), Bujard et al.
patent: 407 122 (1991-01-01), None
patent: 11100327 (1999-04-01), None
patent: WO 95/26409 (1995-10-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO 98/51323 (1998-11-01), None
patent: WO 99/16889 (1999-04-01), None
patent: WO 99/36511 (1999-07-01), None
patent: WO 99/45952 (1999-09-01), None
patent: WO 99/66959 (1999-12-01), None
patent: WO 00/01815 (2000-01-01), None
patent: WO 00/15822 (2000-03-01), None
patent: WO 00/54813 (2000-09-01), None
patent: WO 00/71582 (2000-11-01), None
Auricchio, A. et al. Mol. Therapy. 6(4): 490-494, Oct. 2002.
Romano et al. Stem Cells, 2000, 18:19-39.
Ali et al. Br J Opthalmol, vol. 81, Sep. 1997, pp. 795-801.
Kendall et al. PNAS, vol. 90, Nov. 1993, pp. 10705-10709.
Tolentino, et al., Vascular Endothelial Growth Factor is Sufficient to Produce Iris Neovasularization and Neovascular Glaucoma in a Nonhuman Primate, Arch Opthalmol, vol. 114, pp. 964-970, Aug. 1996.
Oikawa et al., “Three Novel Synthetic Retinoids, Re 80, Am 580 and Am 80, all Exhibit Anti-Angiogenic Activity in vivo”European Journal of Pharmacology 249:113-116, 1993.
Luthert and Chong, “Photoreceptor Rescue”Eye 12:591-596, 1998.
Fotsis et al., “The Endogenous Oestrogen Metabolite 2-Methoxyoestradiol Inhibits Angiogenesis and Suppresses Tumour Growth”Nature 368:237-239, Mar. 17, 1994.
Akimoto et al., “Adenovirally Expressed Basic Fibroblast Growth Factor Rescues Photoreceptor Cells in RCS Rats”Investigative Ophthalmology and Visual Science 40(2) :273-279, Feb. 1999.
Peterson et al., “Enhanced Survival of Photoreceptors in p23h Mutant Rhodopsin Transgenic Rats by Adeno-Associated Virus (AAV) -Madiated Delivery of Neurotrophic Genes”IOVS 39:S1117, Mar. 15, 1998.
Shafiee et al., “Thrombospondin Peptides Inhibit Angiogenesis in Retinal Explant Assay and Rat Model of Retinopathy of Prematurity”IOVS 38:S984, 1997.
Smith et al., “Inhibition of Retinal Neovascularization with an IGF-1 Receptor Antagonist”IOVS 39(4):S450, Mar. 15, 1998.
Cayouette and Gravel, “Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse”Human Gene Therapy 8:423-430, Mar. 1, 1997.
Dwarki Varavani J.
Manning, Jr. William C.
Miller Sheldon S.
Rendahl Katherine
Wang Fei
Baba Edward J.
Bozicevic Field & Francis LLP
Chiron Corporation
Francis Carol L.
The Regents of the University of California
LandOfFree
Use of recombinant gene delivery vectors for treating or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of recombinant gene delivery vectors for treating or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of recombinant gene delivery vectors for treating or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3379716